Hansoh Pharmaceutical Group Co Ltd
3KY
Company Profile
Business description
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
Contact
287 Xiangke Road
Pudong New District
Shanghai201210
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
9,313
Stocks News & Analysis
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks
What now for Santos after takeover offer collapses?
Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks
Morningstar initiates coverage on small cap ASX REIT
Coverage of ASX listed REIT as investor interest in property continues to grow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,061.20 | 20.50 | -0.23% |
| CAC 40 | 7,867.99 | 13.38 | 0.17% |
| DAX 40 | 23,647.57 | 26.96 | -0.11% |
| Dow JONES (US) | 46,173.59 | 31.17 | 0.07% |
| FTSE 100 | 9,231.50 | 3.39 | 0.04% |
| HKSE | 26,545.10 | 0.25 | 0.00% |
| NASDAQ | 22,518.97 | 48.25 | 0.21% |
| Nikkei 225 | 45,045.81 | 257.62 | -0.57% |
| NZX 50 Index | 13,231.66 | 111.63 | 0.85% |
| S&P 500 | 6,636.06 | 4.10 | 0.06% |
| S&P/ASX 200 | 8,773.50 | 18.70 | -0.21% |
| SSE Composite Index | 3,820.09 | 11.57 | -0.30% |